SP

Spectrum Pharmaceuticals IncNASDAQ SPPI Stock Report

Last reporting period 31 Mar, 2023

Updated —

Last price

Market cap $B

0.21

Micro

Exchange

XNAS - Nasdaq

SPPI Stock Analysis

SP

Uncovered

Spectrum Pharmaceuticals Inc is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

-36/100

Low score

Market cap $B

0.21

Dividend yield

Shares outstanding

203.21 B

Spectrum Pharmaceuticals, Inc. is a biotechnology company, which engages in the acquisition, development and commercialization of a pipeline of novel and targeted oncology therapies. The company is headquartered in Henderson, Nevada and currently employs 163 full-time employees. The firm is focused on acquiring, developing, and commercializing targeted oncology therapies. The firm's product portfolio consists of in-development drug products for the treatment of cancer patients. The firm's pipeline products include Eflapegrastim and Poziotinib. The Eflapegrastim is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib is a, pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. The Eflapegrastim employs a LAPSCOVERY technology to enhance the duration of therapeutic effects and reduce the frequency of administration.

View Section: Eyestock Rating